ZEISS Medical Ecosystem - Digital Solutions Roll-out
P&L analysis - High level of investment continues to weigh on margins
Opex ratios trending higher yoy
Gross profit
Selling & marketing
expenses
General admin.
expenses
R&D expenses
EBIT
Adj. EBIT
Carl Zeiss Meditec Group
in € million
549.5
in % of sales
56.4
501.4
58.6
199.6
20.5
160.6
18.8
40.9
33.1
4.2
3.9
165.2
17.0
130.2
15.2
143.9
14.8
177.3
20.7
149.3
15.3
181.3
21.2
6M 2022/23
6M 2021/22
Income Statement
■ Gross margin down yoy based on lower share of recurring
revenue - product mix expected to improve sequentially
■Rise in sales & marketing expenses due to growth
initiatives, in particular Refractive and Surgical
Ophthalmology, higher travel and advertising expenses
☐
☐
Research & development expenses continue on a high level
driven by strategic investments such as digitalization
Delayed effectiveness of price adjustments due to large
order backlog
ZEISS
Page 26View entire presentation